In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma(,)

OBJECTIVE: Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relation...

詳細記述

保存先:
書誌詳細
出版年:Gynecol Oncol
主要な著者: AlHilli, Mariam M., Becker, Marc A., Weroha, S. John, Flatten, Karen S., Hurley, Rachel M., Harrell, Maria I., Oberg, Ann L., Maurer, Matt J., Hawthorne, Kieran M., Hou, Xiaonan, Harrington, Sean C., McKinstry, Sarah, Meng, X. Wei, Wilcoxen, Keith M., Kalli, Kimberly R., Swisher, Elizabeth M., Kaufmann, Scott H., Haluska, Paul
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370566/
https://ncbi.nlm.nih.gov/pubmed/27614696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.08.328
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料